WP-PEP-LRELEDALEQER
Computation-guided 12-mer anticoagulant peptide from Whitmania pigra hydrolysate targeting thrombin Exosite II — Hua 2025 in vivo + SPR validation.
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- Computation-guided 12-mer anticoagulant peptide from Whitmania pigra hydrolysate targeting thrombin Exosite II — Hua 2025 in vivo + SPR validation.
- Evidence level
- Preclinical (animal)
- Drug vs leech
- Synthetic analog
- Safety domains
- Bleeding
Clinical translation limit
WP-PEP-LRELEDALEQER's in vivo anticoagulant activity in rats does NOT establish clinical efficacy. No FDA-approved derivative; W. pigra is a non-hematophagous TCM leech, not the FDA-cleared K040187 medicinal leech.
Molecular Profile
- Category
- Anticoagulant
- Evidence tier
- Preclinical
- Molecular weight
- 1,444 Da
- Source species
- Whitmania pigra
- Discovered
- 2025 · Hua YT et al.
Biological Targets
- → thrombin Exosite II (key residues Arg233 + Arg101)
Key Citations
- Hua YT et al. (2025), J Pept Sci · PMID 40922112
External Resources
Related Anticoagulant Compounds
Hirudin
The most potent natural thrombin inhibitor — and the molecular template for three FDA-approved direct thrombin inhibitor drugs.
Antistasin
Factor Xa inhibitor — prototype molecule that inspired the entire DOAC drug class (rivaroxaban, apixaban).
Ghilanten
Factor Xa inhibitor with anti-metastatic activity in animal cancer models — translational dual-use compound.
Lefaxin
Factor Xa inhibitor with anti-inflammatory properties.